Neoadjuvant Comprehensive Treatment for Unresectable Esophageal Cancer

This study is testing a combination of treatments — immunotherapy, chemotherapy, radiation, and targeted therapy — given before surgery for people with locally advanced esophageal squamous cell cancer (ESCC) that is borderline resectable (not clearly operable at first). The goal is to shrink the tumor enough to allow curative surgery. **You may be eligible if...** - You have confirmed squamous cell carcinoma of the thoracic (chest) esophagus - Your tumor is locally advanced and borderline resectable — suspected but not confirmed to be stuck to nearby structures or with spread to nearby lymph nodes - You have not received any prior cancer treatment - You are in generally good health (KPS score 70 or higher) - Your blood counts, liver, kidney, and other organ functions are within acceptable ranges **You may NOT be eligible if...** - You have another type of cancer at the same time or have had one previously (with limited exceptions) - You have already received any prior cancer treatment - Your cancer has spread to distant sites such as supraclavicular lymph nodes or other organs (metastatic disease) - Your doctor has determined that the tumor is at risk of bleeding from major blood vessels or esophageal perforation - You have active infections, including active hepatitis B, C, or tuberculosis - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.